Scalable production of hiPSC-derived cardiomyocytes in stirred-tank bioreactors

High numbers of high-quality human induced pluripotent stem cells (iPSCs) are required for drug discovery, drug safety testing and regenerative medicine. In this poster, Nold et al demonstrate the suitability of the Eppendorf DASbox® Mini Bioreactor system for the expansion of hiPSCs and subsequent production of Ncardia’s Pluricyte® Cardiomyocytes in a highly reproducible manner.